ACAD•benzinga•
Acadia Pharmaceuticals Key Milestones 2025-2026 Include DAYBUE Marketing Authorization Submitted To EMA; Managed Access In Europe Starts Q2 2025; COMPASS PWS Phase 3 and RADIANT Phase 2 Enrollment and Results Timeline; ACP-204 Lewy Body Dementia Study Beg
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 14, 2025 by benzinga